# EDGAR Filing Document

**Accession Number:** 0001855485
**File Stem:** 0002109116-26-000003
**Filing Date:** 2026-3
**Character Count:** 5480
**Document Hash:** f1769d4c2a7dadcda8da9fa3ec15e21a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0002109116-26-000003.hdr.sgml**: 20260309

**ACCESSION NUMBER**: 0002109116-26-000003

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260309

**DATE AS OF CHANGE**: 20260309

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Calidi Biotherapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001855485
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 862967193
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92875
- **FILM NUMBER:** 26734103

**BUSINESS ADDRESS:**
- **STREET 1:** 4475 EXECUTIVE DRIVE
- **STREET 2:** SUITE 200
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** 858-794-9600

**MAIL ADDRESS:**
- **STREET 1:** 4475 EXECUTIVE DRIVE
- **STREET 2:** SUITE 200
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** First Light Acquisition Group, Inc.
- **DATE OF NAME CHANGE:** 20210406
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Gavrilov Ognian Anguelov
- **CENTRAL INDEX KEY:** 0002109116

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**MAIL ADDRESS:**
- **STREET 1:** 2315 CAPITOL AVENUE
- **CITY:** SACRAMENTO
- **STATE:** CA
- **ZIP:** 95816-5877

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**Calidi Biotherapeutics, Inc.**

*(Name of Issuer)*

**Common Stock, $0.0001 par value**

*(Title of Class of Securities)*

**320703408**

*(CUSIP Number)*

**Chellsea Cartoscelli**<br>2315 Capitol Avenue<br>Sacramento CA 95816<br>9165040529

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**03/09/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **320703408** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Gavrilov Ognian Anguelov** | Name of reporting person<br>**Gavrilov Ognian Anguelov** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**PF** | Source of funds (See Instructions)<br>**PF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**700000.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**700000.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**700000.00** | Aggregate amount beneficially owned by each reporting person<br>**700000.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**9.8%** | Percent of class represented by amount in Row (11)<br>**9.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, $0.0001 par value

**(b) Name of Issuer:**
Calidi Biotherapeutics, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
4475 EXECUTIVE DRIVE, SUITE 200, SAN DIEGO, CA, 92121

**Item 4. Purpose of Transaction**

The Reporting Person acquired the Shares for investment purposes. The Reporting person may from time to time acquire additional shares of common stock or dispose of some or all of the shares in open market transactions, privately negotiated transactions, or otherwise. Except as set forth above, the Reporting Person currently has no plans or proposals which relate to or would result in any of the actions described in clauses a through j of item 3.

**Item 5. Interest in Securities of the Issuer**

**(a)**
700,000 (9.8%)

**(b)**
Sole voting power                         700,000
Shared voting powered              0
Sole dispositive power               700,000
Shared dispositive power         0

**(c)**
None.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Not Applicable

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Gavrilov Ognian Anguelov

**Signature:** Ognian Anguelov Gavrilov

**Name/Title:** Managing Partner

**Date:** 03/09/2026